BioSpace News Archive

Plus Therapeutics, Inc. announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-15.

IDEAYA Biosciences, Inc. announced that, on April 27, 2023, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of the Company’s common stock to a newly hired employee.

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, education and government, advanced technologies and applied materials industries, reported financial results for the first quarter ended March 31, 2023.

Centogene N.V. today announced that it received a notification letter dated April 24, 2023, from the Nasdaq Stock Market LLC Listing Qualifications Department, indicating that the Company was not in compliance with the minimum bid price requirement set forth Rule 5450(a)(1) of the Nasdaq Listing Rules.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.

Aurinia Pharmaceuticals Inc. announced that Glass Lewis & Co., a leading independent proxy advisor, has recommended that Aurinia shareholders vote FOR ALL proposals at the Company’s 2023 Annual General Meeting, including the re-election to the Board of Directors of all eight incumbent directors and the approval of the Company’s say-on-pay resolution.

Evecxia Therapeutics, Inc. today announced that the U.S. Patent and Trademark Office has allowed U.S. patent application 17/877,699.

Galecto, Inc. today announced its operating and financial results for the quarter ended March 31, 2023.

Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and pioneer of robotic-assisted surgery, announced that the Food and Drug Administration recently cleared the da Vinci SP surgical system for simple prostatectomy as a representative procedure, which expands the urologic surgical procedures cleared by FDA.

The Shareholders’ Meeting of Esaote S.p.A., met in Genoa, approved the company’s financial statements at 31.12.2022.